MIRA Pharmaceuticals

Small 🔍 Changes… Big Effects! 💪 Breakthrough Therapies 🚀 Are The Name Of The Game For This Biopharma.🧑🔬 MIRA Pharmaceuticals (NASDAQ: $MIRA) is developing novel treatments⚕️ for neurologic 🧠and neuropsychiatric disorders. 👀 https://lnkd.in/ew5DYPJ6 👀 #pharma #innovation #ad

🔥 $MIRA Exciting News for Mira Pharmaceuticals! 🔥 We're excited to share that Elemer Piros, PhD, from Rodman & Renshaw has initiated coverage of MIRA Pharmaceuticals with a Buy rating and a 12-month price target of $17 per share! Key catalysts from the report: 🚀 Advancing Toward Clinical Trials: Our innovative drug candidates—Ketamir-2 (a next-gen, orally bioavailable ketamine analog) and MIRA-55 (a breakthrough cannabis analog)—are progressing rapidly, with Ketamir-2 set to enter the clinic for neuropathic pain in early 2025. 💡 Ketamir-2 is an unscheduled drug with significant potential as an oral, non-opioid pain management solution, addressing the critical need for alternatives to opioids in light of the ongoing opioid crisis. It's positioned to deliver at-home relief with its superior bioavailability. 🌿 MIRA-55, our second candidate, is a novel chemical entity that combines the therapeutic effects of THC and CBD without the side effects, targeting anxiety and cognitive enhancement. An IND filing for MIRA-55 is planned by year-end 2025, marking another significant milestone on the horizon. 🔍 With the opioid crisis costing the U.S. economy over $1 trillion annually, Mira is committed to offering safe, effective, and innovative non-opioid therapies. Our valuation is driven by the potential future cash flows from Ketamir-2 and beyond, with analysts estimating a $425M NPV through 2044. This is just the beginning—our pipeline is filled with promise, and we’re dedicated to transforming the landscape of pain and psychiatric treatments. Stay tuned for more updates as we push forward in this critical mission. #Biotech #Pharma #Innovation #Opioidcrisis #Clinicaltrials #Painmanagement #Mentalhealth #MIRA #Ketamir2 #MIRA55 #neuropathicPain #Depression #PTSD #FDA

MIRA Pharmaceuticals is advancing the development of an oral ketamine analog, aiming to transform mental health treatment. 💊 This novel formulation seeks to provide a more accessible and patient-friendly alternative to existing ketamine therapies. 🌱 With ongoing research focusing on safety and efficacy, Mira is at the forefront of innovative mental health solutions. 🧠 Their commitment could mark a new chapter in patient care. Know complete story- https://lnkd.in/dDp_EnG8 #MiraPharmaceuticals #MentalHealth #KetamineAnalog #InnovativeTherapies #PatientCare #MentalHealthTreatment 

🚀$MIRA MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion! 🚀 We are excited to announce a major milestone in the development of Ketamir-2, our novel oral ketamine analog. With Phase 1 design complete, we're on track for an IND filing by December 2024. Our innovative Phase 1/2 strategy aims to potentially demonstrate early clinical efficacy for neuropathic pain in 2025, providing critical data that could accelerate decision-making and patient access. This strategy prioritizes early efficacy signals, allowing us to move quickly in addressing key neurologic and neuropsychiatric disorders. Read the full press release for more details: https://lnkd.in/ewdhUjap #NeuropathicPain #ClinicalTrials #Ketamir2 #Biotech #BioTechInnovation #MIRAPharmaceuticals #FDA #HealthcareRevolution

MIRA Pharmaceuticals Wants To Change The Paradigm Of Neuropathic Pain Neuropathic pain is exceptionally difficult to treat. But, there’s a publicly traded biotech company who wants to change that through something new: a novel ketamine analog. MIRA Pharmaceuticals (NASDAQ: MIRA) has officially designated neuropathic pain as the initial and primary indication for their novel oral ketamine analogue therapeutic known as Ketamir-2. What's happening, the big idea, and more: https://lnkd.in/eYHurW-e Featured | cc: Erez Aminov, Dr. Itzchak Angel, Michelle Yanez, MBA, Matthew Del Giudice, Mike Jerman, Ned MacPherson, Denil Shekhat, MD, DABR #biotech #science #healthcare

🚀 $MIRA Exciting Update from MIRA Pharmaceuticals! 🚀 We are thrilled to announce that MIRA (Nasdaq: MIRA) has officially designated neuropathic pain as the primary indication for our novel oral ketamine analog, Ketamir-2! 🎉 We've submitted a request for a pre-IND meeting with the #FDA and are on track to submit our IND by the end of this year, with human trials anticipated to begin in Q1 2025. https://lnkd.in/e59ZatQi Stay tuned for more updates as we continue our journey to transform pain management! #Mira #Pharmaceuticals #NeuropathicPain #Innovation #FDAapproval #Ketamir2 #DiabeticNeuropathy #NeuropathyAwareness #DiabetesCare #NervePain #DiabetesManagement #ChronicPain

MIRA Pharmaceuticals Is Solving Neuropathic Pain With Ketamine MIRA Pharmaceuticals (NASDAQ: MIRA) has announced new pre clinical data validating that their novel oral ketamine analogue known as Ketamir-2 has shown efficacy in significantly reducing neuropathic pain. The oral ketamine analogue Ketamir-2 being developed by MIRA Pharmaceuticals is aiming to provide pain relief without any psychoactive or hallucinogenic effects to patients suffering with neuropathic pain. What's happening, the big idea, and more: https://lnkd.in/eECgjX-n Featured | cc: Erez Aminov, Dr. Itzchak Angel, Michelle Yanez, MBA, Matthew Del Giudice, Mike Jerman, Ned MacPherson, Denil Shekhat, MD, DABR #healthcare #biotech #innovation

$MIRA MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2! We're thrilled to announce a breakthrough: our oral ketamine analog, Ketamir-2, has not only achieved a 100% reversal of neuropathic pain in a recent pre-clinical study but also shows significant promise in treating depression. This dual effectiveness positions Ketamir-2 as a potential game-changer in addressing both neuropathic pain and mental health, offering a more comprehensive solution for patients. As we advance toward clinical trials, we remain committed to bringing this innovative treatment closer to those who need it most. https://lnkd.in/eqmhTYA8 #Pharmaceuticals #NeuropathicPain #DepressionTreatment #Ketamir2 #HealthcareInnovation #Biotech #MIRAPharmaceuticals #Depression #FDA

MIRA Pharmaceuticals ( $MIRA) Introduces Nor-Ketamir – an Extended Duration, Brain-Penetrating, and Selective Compound Targeting the NMDA PCP Receptor https://lnkd.in/eg8xytGK #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia

🚀 $MIRA Exciting Developments at MIRA Pharmaceuticals! 🚀 We’re excited to share new preclinical data on Ketamir-2 and its principal metabolite Nor-Ketamir! This innovative compound is showing promising potential as a longer-acting, brain-penetrating, and highly selective treatment for neurological disorders. Key Findings: Enhanced Bioavailability: Nor-Ketamir demonstrates nearly 100% oral bioavailability in preclinical studies. Prolonged Therapeutic Potential: Extended half-life and sustained brain penetration could make it suitable for at-home treatment. Improved Safety Profile: A cleaner pharmacological profile, potentially reducing risks compared to existing options. While we’re still in the early stages, these findings are a significant step forward in our mission to explore safer and more effective treatments for neurological conditions. We’re looking forward to the next stages of development. 💊 https://lnkd.in/e-gcU78f #Neuroscience #Pharmaceuticals #Innovation #Ketamir2 #MentalHealth #MIRAPharma #Depression #NeuropathicPain #FDA #PTSD